Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$34.25 USD
+0.75 (2.24%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $34.39 +0.14 (0.41%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for Corbus Pharmaceuticals Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 1 | 4 | 36 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 1 | 4 | 36 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 40 | 57 | 127 | 113 |
Income After Depreciation & Amortization | -45 | -40 | -56 | -123 | -77 |
Non-Operating Income | 3 | 0 | 12 | 12 | 6 |
Interest Expense | 3 | 2 | 2 | 0 | 0 |
Pretax Income | -45 | -42 | -46 | -111 | -71 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -45 | -42 | -46 | -111 | -71 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -45 | -42 | -46 | -111 | -71 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -44 | -37 | -53 | -121 | -76 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -45 | -40 | -56 | -123 | -77 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.33 | 4.17 | 4.10 | 2.60 | 2.13 |
Diluted EPS Before Non-Recurring Items | -10.31 | -8.95 | -11.11 | -42.64 | -33.63 |
Diluted Net EPS (GAAP) | -10.31 | -10.15 | -11.11 | -42.64 | -33.63 |
Fiscal Year end for Corbus Pharmaceuticals Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.10 | 9.49 | 8.19 | 17.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -10.10 | -9.49 | -8.19 | -17.30 |
Non-Operating Income | NA | 2.79 | 0.20 | 0.18 | -0.45 |
Interest Expense | NA | 1.39 | 0.76 | 0.78 | 0.00 |
Pretax Income | NA | -8.02 | -10.05 | -8.78 | -17.74 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.02 | -10.05 | -8.78 | -17.74 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.02 | -10.05 | -8.78 | -17.74 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 4.42 | 4.42 | 4.28 | 4.18 |
Diluted EPS Before Non-Recurring Items | NA | -1.81 | -2.27 | -2.05 | -4.24 |
Diluted Net EPS (GAAP) | NA | -1.75 | -2.27 | -2.05 | -4.24 |